What is OGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.62B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OGN?

P/E (TTM) is 17.30 and 52-week range is $5.69 to $13.83 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OGN?

The company profile lists revenue (TTM) near $5.95B, net income (TTM) near $203M, EPS (TTM) near $0.78 when available from the market-data feed. Figures are informational and may lag live markets.

Does OGN show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $0.07, yield near 0.50%, ex-dividend date Aug 14, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Organon & Co based, and what identifiers does Chartloom list?

The company context section lists headquarters in Jersey City, New Jersey, US, 262.6M shares outstanding, ISIN US68622V1061 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Organon & Co

$OGN

Health Care · Pharmaceuticals

IR Run Scenarios

$13.77

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Employees

10,000

Website

www.organon.com/

IPO

2021-05-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)